Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders

Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
Santé log

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly ...

Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU

Regeneron Pharmaceuticals and Sanofi have won expanded European regulatory approval of their blockbuster anti-inflammatory drug Dupixent for younger patients with the inflammatory skin condition ...